Consistency and proportionality in policy decision-making in blood safety: The case for an all-apheresis platelet supply in Germany

Clinical Laboratory

Volumn 59, Issue 1-2, 2013, Pages 1-22

  Vamvakas, Eleftherios C ^b   Hitzler, W E ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS RNA;

APHERESIS; BLOOD SAFETY; CLINICAL DECISION MAKING; DISEASE SURVEILLANCE; GERMANY; HEALTH CARE POLICY; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MATHEMATICAL MODEL; REVIEW; RISK FACTOR; RISK REDUCTION; SCREENING TEST; THROMBOCYTE COUNT; TRANSFUSION RELATED ACUTE LUNG INJURY; VIRUS TRANSMISSION;

EID: 84874593227     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: 10.7754/Clin.Lab.2012.121012     Document Type: Review

References (100)

1. Offergeld R, Ritter S, Kamp C, et al. Differences in infection risks between pool and apheresis platelets - a mathematic model. Transfus Med Hemother 2012;39(suppl 1):1-66. Abstract # P 3.02.
2. Vamvakas EC. Causes of mortality related to allogeneic blood transfusion. In: Vamvakas EC. Decision-Making in Transfusion Medicine. Bethesda, MD: American Association of Blood Banks Press, 2011, pp. 31-85.
3. Vamvakas EC. Reasons for moving toward a patient-centric paradigm of clinical transfusion medicine practice. Transfusion 2012 (Epub ahead of print, Aug 6). Available at: http://www.aabb.org/resources/bct/pbm/Documents/paradigm- shifts.pdf
4. US Department of Health and Human Services. The 2009 national blood collection and utilization survey report. Washington, DC: DHHS, 2011.
5. FDA/CBER. Fatalities reported to the FDA following blood collection and transfusion. Annual summary for fiscal year 2010. Available at: http://www.fda.gov/downloads/BiologicsBloodVaccines/SafetyAvailability/ ReportaProblem/TransfusionDonationFatalities/UCM254860.htm
6. Vamvakas EC, Blajchman MA. Transfusion-related mortality: The on-going risks of allogeneic blood transfusion and the available strategies for their prevention. Blood 2009;113:3406-17.
7. Vamvakas EC, Blajchman MA. Blood still kills: Six strategies to further reduce allogeneic blood transfusion-related mortality. Transfus Med Rev 2010;24:77-124.
8. Dodd RY, Leiby DA. Emerging infectious threats to the blood supply. Am Rev Med 2004;55:191-207. (Pubitemid 38316723)
9. Alter HJ, Stramer SL, Dodd RY. Emerging infectious diseases that threaten the blood supply. Semin Hematol 2007;44:32-41. (Pubitemid 46013927)
10. Stramer SL, Hollinger FB, Katz LM, et al. Emerging infectious disease agents and their potential threat to transfusion safety. Transfusion 2009 (Suppl. 2);49:1S-236S.
11. Dodd RY. Emerging infections, transfusion safety, and epidemiology. N Engl J Med 2003;349:1205-6. (Pubitemid 37152029)
12. Vamvakas EC, Taswell HF. Long-term survival after blood transfusion. Transfusion 1994;34:471-7. (Pubitemid 24209656)
13. th ed., 2009, pp. 33-4.
14. Ness P, Braine N, King K, et al. Single-donor platelets reduce the risk of septic platelet transfusion reactions. Transfusion 2001;41:857-61. (Pubitemid 32642756)
15. Ness PM, Campbell-Lee SA. Single-donor versus pooled random-donor platelet concentrates. Curr Opin Hematol 2001;8:392-6. (Pubitemid 33032922)
16. Vamvakas EC. Relative safety of pooled whole-blood-derived versus single-donor (apheresis) platelets in the United States: A systematic review of disparate risks. Transfusion 2009;49:2743-58.
17. Vamvakas EC. The relative safety of pooled whole-blood-derived platelets prepared by the buffy-coat method versus single-donor (apheresis) platelets. Clin Lab 2010;56:263-79.
18. Reports on Notifications Pursuant to § 21 German Transfusion Act, Paul-Ehrlich Institute. Available at: http://www.pei.de/cln-330/nn-156172/DE/ infos/meldepflichtige/meldung-blutprodukte-21-transfusionsgesetz/berichte/ berichte-21-tfg-node.html?-nnn=true#doc156176bodyText4
19. Stellungnahme des Paul-Ehrlich-Instituts (PEI) zur Sicherheit von Pool-Thrombozytenkonzentraten (PTK) und Apherese-Thrombozytenkonzentraten (ATK) (German). Paul-Ehrlich-Institut (PEI) 29.11.2011. Available at: http://www.pei.de/DE/arzneimittelsicherheit-vigilanz/archiv- sicherheitsinformationen/2011/ablage2011/2011-11-29-haemovigilanz-stellungnahme- sicherheit-ptk-atk.html
20. Schriftliche und mündliche Stellungnahme des Paul-Ehrlich-Institut (PEI) zur Anhörung im Sozialpolitischen Ausschuss des Landtag Rheinland-Pfalz, 9. Sitzung am 08.03.2012 (German).
21. Funk MB, et al. Hämovigilanz-Bericht des Paul-Ehrlich-Instituts 2010: Auswertung der Meldungen von schwerwiegenden Transfusionsreaktionen nach § 63c AMG, 2012 (German). Available at: http://www.pei.de/ haemovigilanzbericht
22. Funk MB, et al. Hämovigilanz-Bericht des Paul-Ehrlich-Instituts 2009: Auswertung der Meldungen von schwerwiegenden Transfusionsreaktionen nach § 63c AMG, 2011(German). Available at: http://www.pei.de/ haemovigilanzbericht
23. Funk MB, Gönay S, Lohmann, et al. Haemovigilance Report 1997-2008: Assessment of reports of serious adverse transfusion reactions, Paul-Ehrlich-Institut 2010. Available at: http://www.pei.de/hv-report
24. Kleinman S, Caulfield T, Chan P, et al. Toward an understanding of transfusion-related acute lung injury: Statement of a consensus panel. Transfusion 2004;44:1774-89. (Pubitemid 39644064)
25. Robillard P, Hyson C, McCombie N. TRALI, possible TRALI and respiratory complications of transfusion reported to the Canadian Transfusion-Transmitted Injuries Surveillance System. Transfusion 2007;47(Suppl.):5A.
26. Gajic O, Rana R, Winters JL, et al. Transfusion-related acute lung injury in the critically ill: Prospective nested case-control study. Am J Respir Crit Care Med 2007;176:886-91. (Pubitemid 350097078)
27. Silliman CC, Ambruso DR, Boshkov LK. Transfusion-related acute lung injury. Blood 2005;105:2266-73. (Pubitemid 40387018)
28. Robillard P, Nawej KI, Jochem K. The Quebec hemovigilance system: Description and results from the first two years. Transfus Apher Sci 2004;31:111-22. (Pubitemid 40292136)
29. Andreu G, Morel P, Forester F, et al. Hemovigilance network in France: Organization and analysis of immediate transfusion incident reports from 1994 to 1998. Transfusion 2002;42:1356-64.
30. Serious hazards of transfusion (SHOT) Annual Reports. Available at: http://www.shot-uk.org
31. Stainsby D, Jones H, Asher D, et al. Serious hazards of transfusion: A decade of hemovigilance in the UK. Transfus Med Rev 2006;20:237-82.
32. th, Stramer SL. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion 2002;42:975-9.
33. Roth VR, Kuehnert MJ, Haley NR, et al. Evaluation of a reporting system for bacterial contamination of blood components in the United States. Transfusion 2001;41:1486-92. (Pubitemid 34072671)
34. Zou S, Wu Y, Cable R, et al. A prospective study of multiple-donor- exposure blood recipients: Surveillance value and limitations for hemovigilance. Transfusion 2010;50:128-38.
35. Tambyah PA, Koay ESC, Poon MLM, Lin RVTP, Ong BKC. Dengue hemorrhagic fever transmitted by blood transfusion. N Engl J Med 2008;359:1526-7.
36. Seed CR, Kiely P, Hyland CA, Keller AJ. The risk of dengue transmission by blood during a 2004 outbreak in Cairns, Australia. Transfusion 2009;49:1482-7.
37. DasErste.de, WDR: Monitor1: Trotz des Aids-Skandals: Kassen wollen wieder gemischtes Blut. [Despite the AIDS scandal: Health insurance companies want pooled blood again.]. Available at: http://www.wdr.de/tv/monitor//sendungen/ 2011/1124/blut.php5
38. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ. The risk of transfusion-transmitted viral infections. N Engl J Med 1996;334:1685-90. (Pubitemid 26193619)
39. Hourfar MK, Tork C, Schottstedt V, et al. Experience of German Red Cross blood donor services with nucleic acid testing: results of screening more than 30 million blood donations for human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus. Transfusion 2008;48:1558-66.
40. Leiss W. Tyshenko M, Krewski D. Men-having-sex-with-men donor-deferral risk assessment: An analysis using risk-management principles. Transf Med Rev 2009;23:85-102.
41. Further guidance on methods to detect bacterial contamination of platelet components. AABB Association Bulletin #03-12 (October 1, 2003). Bethesda, MD: AABB, 2003. Available at: http://www.aabb.org/resources/publications/bulletins/ Documents/obsolete/AB%2003-12%20OBSOLETE.pdf
42. Stohlawetz P, Stiegler G, Jilma B, et al. Measurement of the levels of reticulated platelets after plateletpheresis to monitor activity of thrombopoiesis. Transfusion 1998;38:454-8. (Pubitemid 28287502)
43. Lazarus EF, Browning J, Norman J, et al. Sustained decreases in platelet counts associated with multiple, regular plateletpheresis donations. Transfusion 2001;41:756-61. (Pubitemid 32538509)
44. Amrein K, Katsching C, Sipurzynski S, et al. Apheresis affects bone and mineral metabolism. Bone 2010;46:789-95.
45. Kamel H, Tomasulo P, Bravo M, et al. Delayed adverse reactions to blood donation. Transfusion 2010;50:556-65.
46. Schrezenmeier H, Seifried E. Buffy-coat-derived pooled platelet concentrates and apheresis platelet concentrates: Whch product type should be preferred? Vox Sang 2010;99:1-15.
47. Vamvakas EC. The ethics of wasting the donor's gift of buffy coat. Vox Sang 2010; 100:256-7.
48. Foster KR, Vecchia P, Repacholi MH. Science and the precautionary principle. Science 2000;288:979-81. (Pubitemid 30324222)
49. Wilson K, Wilson M, Hébert PC, Graham I. The application of the precautionary principle to the blood system: the Canadian blood system's vCJD donor deferral policy. Transf Med Rev 2003;17:89-94. (Pubitemid 36546194)
50. Commission of the European Communities. Communication from the Commission on the Precautionary Principle. Brussels: European Commission, 2000.
51. Jonglerius JM, Wester M, Cuypers HTM, et al. New hepatitis B virus mutant form in a blood donor that is undetectable in several hepatitis B surface antigen screening assays. Transfusion 1998;38:56-9. (Pubitemid 28090941)
52. Paul-Ehrlich Institut. Anordnung von Maßnahmen zur Risikominimierung beim Einsatz von HIV-1 NAT-Testsystemen, 15. June 2012 (German). Available at: http://www.pei.de/cln-227/nn-2058936/SharedDocs/ Downloads/vigilanz/haemovigilanz/bescheide/2012-06-15-anordnung-massnahmen- risikominimierung-hiv-1-nat-testsysteme.html
53. Schmidt M, Korn K, Nubling M, et al. First transmission of human immunodeficiency virus type 1 by a cellular blood product after mandatory nucleic-acid screening in Germany. Transfusion 2009;49:1836-44.
54. Klein HG, Anderson D, Bernardi MJ, et al. Pathogen inactivation: making decisions about new technologies. Report of a consensus conference. Transfusion 2007;47:2338-47. (Pubitemid 350151213)
55. Kerkhoffs JL, van Putten WL, Novotny VM, et al. Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction. Br J Haematol 2010;150:209-17.
56. Vamvakas EC. Meta-analysis of the randomized controlled trials of the hemostatic efficacy and capacity of pathogen-reduced platelets. Transfusion 2011;51:1058-71.
57. Van Rhenen D, Gulliksson H, Cazenave JP, et al. Transfusion of pooled buffy-coat platelet components prepared with a photochemical pathogen inactivation treatment: The euroSPRITE trial. Blood 2003;101:2426-33. (Pubitemid 36302092)
58. Snyder E, McCullough J, Slichter SJ, et al. Clinical safety of platelets photochemically-treated with amotosalen HCl and ultraviolet A light for pathogen inactivation: the SPRINT trial. Transfusion 2005;45:1864-75. (Pubitemid 43971413)
59. Janetzko K, Cazenave JP, Kluter H, et al. Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set. Transfusion 2005;45:1443-52. (Pubitemid 44194647)
60. The Mirasol Clinical Evaluation Study Group. A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology. Transfusion 2010;50:2362-75.
61. Roth GJ, Hickey MJ, Chung DW, Hickstein DD. Circulating human blood platelets retain appreciable amounts of poly (A)+ RNA. Biochem Biophys Res Commun 1989;160:705-10. (Pubitemid 19140590)
62. Bugert P, Dugrillon A, Gunaydin A, Eichler H, Kluter H. Messenger RNA profiling of human platelets by microarray hybridization. Thromb Haemost 2003;90:738-48. (Pubitemid 37287644)
63. Gnatenko DV, Dunn JJ, McCorkle SR, Weissmann D, Perrotta PL, Bahou WF. Transcript profiling of human platelets using microarray and serial analysis of gene expression. Blood 2003;101:2285-93. (Pubitemid 36302071)
64. McRedmond JP, Park SD, Reilly DF, et al. Integration of proteomies and genomics in platelets: a profile of platelet proteins and platelet-specific genes. Mol Cell Proteomics 2004;3:133-44. (Pubitemid 38714271)
65. Rowley JW, Oler A, Tolley ND, et al. Genomewide RNA-seq analysis of human and mouse platelet transcriptomes. Blood 2011;118:e101-11.
66. Tsao CH. Rough endoplasmic reticulum and ribosomes in blood platelets. Scand J Haematol 1971;8:134-40.
67. Kieffer N, Guichard J, Farcet JP, Vainchenker W, Breton-Gorius J. Biosynthesis of major platelet proteins in human blood platelets. Eur J Biochem 1987;164:189-95. (Pubitemid 17053683)
68. Booyse FM, Rafelson ME, Jr. Studies on human platelets. I. Synthesis of platelet protein in a cell-free system. Biochim Biophys Acta 1968;166:689-97.
69. Weyrich AS, Dixon DA, Pabla R, et al. Signal-dependent translation of a regulatory protein, Bcl-3, in activated human platelets. Proc Natl Acad Sci U S A 1998;95:5556-61. (Pubitemid 28224133)
70. Evangelista V, Manarini S, Di Santo A, et al. De novo synthesis of cyclooxygenase-1 counteracts the suppression of platelet thromboxane biosynthesis by aspirin. Circ Res 2006;98:593-5.
71. Landry P, Plante I, Ouellet DL, Perron MP, Rousseau G, Provost P. Existence of a microRNA pathway in anucleate platelets. Nat Struct Mol Biol 2009;16:961-6.
72. Edelstein LC, Bray PF. MicroRNAs in platelet production and activation. Blood 2011;117:5289-96.
73. Bruchova H, Merkerova M, Prchal JT. Aberrant expression of microRNA in polycythemia vera. Haematologica 2008;93:1009-16. (Pubitemid 351957018)
74. Nagalla S, Shaw C, Kong X, et al. Platelet microRNA-mRNA coexpression profiles correlate with platelet reactivity. Blood 2011;117:5189-97.
75. Osman A, Falker K. Characterization of human platelet micro-RNA by quantitative PCR coupled with an annotation network for predicted target genes. Platelets 2011;22:433-41.
76. Kondkar AA, Bray MS, Leal SM, et al. VAMP8/endobrevin is overexpressed in hyperreactive human platelets: suggested role for platelet microRNA. J Thromb Haemost 2010;8:369-78.
77. Hitzler W, Vamvakas EC. Platelet microRNA profiles and the effect of pathogen reduction on platelet function. Clin Lab 2011;57:451-4.
78. Vamvakas EC. Meta-analysis of the studies of bleeding complications of platelets pathogen-reduced with the Intercept system. Vox Sang 2012;102:302-16.
79. Lozano M, Knutson F, Tardivel R, et al. A multicenter study of the therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet-A pathogen inactivation stored for 6 or 7 days prior to transfusion. Br J Haematol 2011;153:393-401.
80. Cid J, Escolar G, Lozano M. Therapeutic efficacy of platelet components treated with amotosalen and ultraviolet A pathogen inactivation method: results of a meta-analysis of randomized controlled trials. Vox Sang 2012 (Epub ahead of print, May 7).
81. McCullough J, Vesole DH, Benjamin RJ, et al. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: The SPRINT trial. Blood 2004;104:1534-41. (Pubitemid 39166535)
82. FDA/CBER. Study Designs (Phases 3 and 4) for Product Development of Human Platelets Using the Cerus INTERCEPT Blood System for Pathogen Inactivation. Meeting of the Blood Products Advisory Committee: November 16, 2009.
83. Stein J, Bersley J, Brook C, et al. Risk-based decision-making for blood safety: Preliminary report of a consensus conference. Vox Sang 2011;101:277-81.
84. Jakobs MR, Smith D, Heaton WA, Good CE: Detection of bacterial contamination in prestorage culture-negative apheresis platelets on day of issue with the Pan Genera Detection Test. Transfusion 2011;51:2573-82.
85. Recommendations to address residual risk of bacterial contamination of platelets. AABB Association Bulletin #12-04 (October 4, 2012). Bethesda, MD: AABB, 2012. Available at : http://www.aabb.org/resources/publications/bulletins/ Pages/ab12-04.aspx
86. Popovsky MA. Transfusion-related acute lung injury : Incidence, pathogenesis, and the role of multicomponent apheresis in its prevention. Transfus Med Hemother 2008;35:76-9. (Pubitemid 351555896)
87. Farrugia A. Falsification or paradigm shift? Toward a revision of the common sense of transfusion. Transfusion 2011;51:216-24.
88. van Stein D, Beckers EA, Sintnicolaas K, et al. Transfusion-related acute lung injury in the Netherlands: an observational study. Transfusion 2010;50:213-20.
89. Win N, Chapman CE, Bowles KM, et al. How much residual plasma may cause TRALI? Transfus Med 2008;18:276-80.
90. Vamvakas E. Reasons for moving toward a patient-centric paradigm of clinical transfusion medicine practice. Presented at the Annual Meeting of the Swiss Association for Transfusion Medicine, Basel, Switzerland, 9/7/2012. Available at: http://www.swisstransfusion.ch/fileadmin/images/inhaltselemente/ 2012/Praesentationen/Vamvakas-Reasons-for-moving-toward-a-patient-centric- paradigm-of-clinical-transfusion-medicine-practice.pdf
91. Whitaker BK, Green J, King MR, et al. The 2007 national blood collection and utilization survey report. Washington, DC: Department of Health and Human Services, 2008.
92. Slichter SJ, Kaufman RM, Assman SF, et al. Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med 2010;362:600-13.
93. Paul-Ehrlich Institut. Einführung Risiko- minimierender Maßnahmen zur Prävention von West Nil Virus-Übertragung durch nicht pathogen-inaktivierte Blutkomponenten, 16. November 2011 (German). Available at: http://www.pei.de/SharedDocs/Downloads/vigilanz/haemovigilanz/ anhoerungen/2011-11-16-wnv-stufel.templateId=raw.property=publicationFile.pdf/ 2011-11-16-wnv-stufel.pdf
94. European Center for Disease Prevention and Control. West Nile fever maps. Available at: http://www.ecdc.europa.eu/en/healthtopjcs/west-nile-fever/West- Nile-fever-maps/Pages/index.aspx
95. Petersen LR, Hayes EB. Westward ho? The spread of West Nile virus. N Engl J Med 2004;351:2257-9. (Pubitemid 39552739)
96. Vamvakas E, Kleinman S, Hume H, Sher GD. The development of West Nile Virus safety policies by Canadian Blood Services: Guiding principles and a comparison between Canada and the United States of America. Transfus Med Rev 2006;20: 97-109.
97. Custer B, Agapova M, Martinez RH. The cost-effectiveness of pathogen reduction technology as assessed using a multiple risk reduction model. Transfusion 2010;50:2461-73.
98. Rossini G, Gavrini F, Pierro A, et al. First human case of West Nile virus neuroinvasive infection in Italy, September 2008 (case report). Euro Surveill 2008;13.pii:19002.
99. Barzon L, Pacenti M, Franchin E, et al. Clinical and virological findings in the ongoing outbreak of West Nile virus Livenza strain in Northern Italy, July to September 2012. Euro Surveill 2012;17.pii 20260. Available at: http://www.eurosurveillance.org/ViewArticle.aspx?Articleid=20260
100. Barzon L, Pacenti M, Franchin E, et al. Novel West Nile virus lineage Ia full genome sequences from human cases of infection in north-eastern Italy, 2011. Clin Microbiol Infect 2012 (Epub ahead of print, Aug 31).